ClinicalTrials.gg
Not yet recruitingNCT06272565DRUpdated Jul 1, 2024

Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage

An observational study in Diabetic Retinopathy, Diabetic Macular Edema and Anti-vascular Endothelial Growth Factor, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
240
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Retinopathy · Zhongshan Ophthalmic Center, Sun Yat-sen University.

Started
2024
with 1 other
Observational
6 of 10
4 open now
Registered
6th of 10
by date

Among the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, this one is one of 2 that started in 2024, is one of 6 observational ones, and was the 6th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

7 of the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, or all of them as a file.
02

Study summary

Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.

03

Conditions studied

  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Anti-vascular Endothelial Growth Factor

Browse trials for

Keywords

  • Diabetic retinopathy
  • metabolomics
  • NLPR3
  • Diabetic Macular edema
  • Anti-vascular endothelial growth factor
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. CON (non diabetes control group):Non diabetes patients undergoing phacoemulsification surgery.
  2. NDR (non diabetes retinopathy diabetes patients): Non DR diabetes patients undergoing phacoemulsification surgery.
  3. NPDR (non proliferative diabetes retinopathy): DR patients with no sign of any neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery.
  4. PDR (proliferative diabetes retinopathy): DR patients with neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients > 40 years old.
  2. CON (non diabetes control group):patients undergoing phacoemulsification surgery.
  3. NDR (non diabetes retinopathy diabetes patients): patients with diabetes history and undergoing phacoemulsification surgery.
  4. NPDR (non proliferative diabetes retinopathy): patients with history of diabetes, fundus microangiopathy shown by fundus fluorescein angiography, including microangioma, hard exudation, wadding exudation and other non proliferative diabetes retinopathy signs, and did not receive invasive ophthalmic treatment within 3 months.
  5. PDR (proliferative diabetes retinopathy): patients with a history of diabetes, fundus neovascular lesions shown by fundus fluorescein angiography, and did not receive invasive ophthalmic treatment within 3 months.
  6. Patients voluntarily signed .

Exclusion criteria

Exclusion Criteria:

  1. CON (non diabetes control group):patients with a history of other ophthalmic operations.
  2. NDR (non diabetes retinopathy diabetes patients): patients with fundus changes of diabetes retinopathy or other ophthalmic surgery history.
  3. NPDR (non proliferative diabetes retinopathy): patients with fundus neovascular lesions shown by fundus fluorescein angiography.
  4. PDR (proliferative diabetes retinopathy):patients undergoing vitrectomy。
  5. Patients with active ocular inflammation, high myopia, pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • CON(Non diabetes control group)

    Non diabetes patients undergoing phacoemulsification surgery

  • NDR(Non diabetes retinopathy diabetes patients)

    Non DR diabetes patients undergoing phacoemulsification surgery

  • NPDR (non proliferative diabetes retinopathy)

    DR patients with no sign of any neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery

  • PDR (proliferative diabetes retinopathy)

    DR patients with neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery

06

What researchers measure

Primary outcomes

  1. Untargeted metabolomics for metabolic profile using UHPLC/MS

    Aqueous humor samples in DR patients will be analysed to putatively identify metabolic profile by comparison with control samples using ultra-high performance liquid chromatography-high resolution mass spectrometer (UHPLC/MS). UHPLC/MS analysis allows the simultaneous high-resolution measurement of a broad range of metabolites, hence the untargeted nature of the analysis. For the UHPLC/MS results, perform normalization, standardization, and log transformation, then compare the metabolite differences between groups. Multivariate statistical analysis and Partial least squares discriminant analysis included in the mass spectrometry software will be used to analyse UHPLC/MS results to identify metabolites that best discriminate between DR and control conditions. The evaluation of significant metabolite results is based on: P-value and Fold change.

    Time frame: 24 weeks

Secondary outcomes

  1. Best-corrected visual acuity

    Best-corrected visual acuity at baseline and 24 weeks follow-up

    Time frame: 24 weeks

  2. Central subfield thickness

    Central subfield thickness at baseline and 24 weeks follow-up

    Time frame: 24 weeks

07

Study locations

1 site
  • Zhongshan Ophthalmic Center of Sun Yat-sen University
    Guangzhou, Guangdong 510623, China
    • Zhongshan Ophthalmic Center of Sun Yat-sen University · Contactchh5413@126.com · 86+13560323773
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Dec 2026, 29 months later.

Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 29 months is close to that.

Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 22, 2024
StartEst.
Jul 3, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06272565
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Jul 3, 2024 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 1, 2024

Study contacts

Hui Chen, PHD
Contact
chh5413@126.com
0086-20-87330000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion